Case number 1:21-cv-00425
Astellas Pharma Inc. et al v. Aurobindo Pharma Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 30, 2023 | 37 | STIPULATION and [Proposed] Order Regarding Motion for Attorneys' Fees and Related Costs by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Silver, Daniel) (Entered: 06/30/2023) (3) |
| Jun 28, 2023 | 36 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 34 Notice of Appeal (Federal Circuit) filed by Astellas Ireland Co., Ltd., Astellas Pharma Inc., Astellas Pharma Global Development, Inc.. USCA Case Number 2023-2089 (mpb) (Entered: 06/28/2023) (4) |
| Jun 22, 2023 | 35 | MOTION Defendants' Motion Pursuant to Fed. R. Civ. P. 52(b) for Additional Findings in Support of Court's Judgment in Favor of Defendants re 32 Judgment - filed by Zydus Pharmaceuticals (USA) Inc.. Motions referred to Christopher J. Burke.(Kraman, Pilar) (Entered: 06/22/2023) (7) |
| Jun 21, 2023 | 34 | NOTICE OF APPEAL to the Federal Circuit of 32 Judgment . Appeal filed by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Silver, Daniel) (Entered: 06/21/2023) (2) |
| Jun 9, 2023 | 33 | Final Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,842,780. (twk) (Entered: 06/09/2023) (1) |
| Jun 9, 2023 | 32 | JUDGMENT. (CASE CLOSED). Signed by Judge Joseph F. Bataillon on 6/9/2023. Associated Cases: 1:20-cv-01589-JFB-CJB, 1:21-cv-00425-JFB-CJB, 1:21-cv-00664-JFB-CJB(twk) (Entered: 06/09/2023) (1) |
| Jun 9, 2023 | 31 | MEMORANDUM AND ORDER, claims 5, 20, and 25 of U.S. Patent No. 10,842,780 are invalid. All pending motions are denied as moot. (See Order for further details). Signed by Judge Joseph F. Bataillon on 6/9/2023. Associated Cases: 1:20-cv-01589-JFB-CJB, 1:21-cv-00425-JFB-CJB, 1:21-cv-00664-JFB-CJB(twk) (Entered: 06/09/2023) (4) |
| Dec 6, 2022 | 30 | STIPULATION of Dismissal as to Defendants Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc. and Aurolife Pharma LLC by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Joyce, Alexandra) (Entered: 12/06/2022) (2) |
| Nov 2, 2022 | 29 | STIPULATION of Dismissal that all claims against Actavis and by Actavis against Plaintiffs are dismissed without prejudice by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Joyce, Alexandra) (Entered: 11/02/2022) (2) |
| Aug 13, 2021 | 28 | Stipulation and Order (5) Docket Text: STIPULATION AND ORDER Dismissing Defendant Actavis LLC, without prejudice. Signed by Judge Joseph F. Bataillon on 8/13/2021. Associated Cases: 1:20-cv-01589-JFB-CJB, 1:21-cv-00425-JFB-CJB(nmg) |
| Aug 12, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Jason A. Leonard for Astellas Ireland Co., Ltd.,for Astellas Pharma Global Development, Inc., for Astellas Pharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Aug 11, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Entry made today at D.I. 28 NOTICE of Withdrawal of Their Motion to Dismiss and Stipulation to Forgo Answers has been removed from this docket at the request of the filer. All filings for this case should be filed in the Lead Case docket per the consolidation order. (dlb) |
| Aug 11, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED D.I.[7] MOTION for Pro Hac Vice Appearance of Attorney Simon D. Roberts and Jason A. Leonard filed by Astellas Ireland Co., Ltd., Astellas Pharma Inc., Astellas Pharma Global Development, Inc. Ordered by Judge Christopher J. Burke on 8/11/2021. (dlb) |
| Aug 11, 2021 | N/A | Order Setting Briefing Schedule (0) Docket Text: SO ORDERED D.I. [25] STIPULATION TO EXTEND TIME the Deadline for Plaintiffs to file their Answering Brief in Opposition to Defendants Motion to Dismiss Under Fed. R. Civ. P. 12(b)(6) to August 12, 2021, D.I.[15] STIPULATION TO EXTEND TIME move, plead or otherwise respond to the Complaint to July 29, 2021, D.I. [23] STIPULATION TO EXTEND TIME the Deadline for Plaintiffs to file their Answering Brief in Opposition to Defendants Motion to Dismiss Under Fed. R. Civ. P. 12(b)(6) to August 5, 2021,D.I.[16] STIPULATION TO EXTEND TIME for Lupin Pharmaceuticals, Inc. to answer, move or otherwise respond to the Complaint to July 15, 2021, and D.I. [24] STIPULATION TO EXTEND TIME (and proposed order) for defendants Actavis Elizabeth LLC, Actavis LLC, and Teva Pharmaceuticals USA, Inc. to answer, move, or otherwise respond to plaintiff's complaint to August 12, 2021. Ordered by Judge Christopher J. Burke on 8/11/2021. (dlb) |
| Aug 11, 2021 | N/A | Create Case Association (0) Docket Text: Cases associated with lead case 20-1589, please docket all future entries in this lead case docket only. Ordered by Judge Christopher J. Burke on 8/11/2021. Associated Cases: 1:21-cv-00425-JFB-CJB, 1:21-cv-00664-JFB(dlb) |
| Aug 11, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED D.I. (155 in 1:20-cv-01589-JFB-CJB, 10 in 1:21-cv-00664-JFB, 26 in 1:21-cv-00425-JFB-CJB) Stipulation to Consolidate cases filed by Astellas Ireland Co., Ltd., Astellas Pharma Inc., Astellas Pharma Global Development, Inc. The LEAD Case shall be 20-1589-JFB-CJB and all future docket entries for these cases shall be made in the lead case only. Ordered by Judge Christopher J. Burke on 8/11/2021. Associated Cases: 1:20-cv-01589-JFB-CJB, 1:21-cv-00425-JFB-CJB, 1:21-cv-00664-JFB(dlb) |
| Aug 6, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER Pursuant to the filing of this case, the Court issues the following order: Magistrate Judge Christopher J. Burke shall issue a scheduling order when appropriate. Magistrate Judge Burke shall handle all nondispositive matters on all issues, except for Daubert motions, Markman hearings, and pretrial motions in limine. The parties have the right to file an appeal of the magistrate judge's order, and the same shall be decided by the undersigned. The magistrate judge shall likewise handle all discovery matters, scheduling, and pretrial conferences. If the parties believe the magistrate judge has a conflict of interest with this case, the parties shall so notify the Court. IT IS SO ORDERED. Signed by Judge Joseph F. Bataillon on 08/06/21. (AEV) |
| Aug 5, 2021 | 26 | Stipulation (7) Docket Text: STIPULATION and [Proposed] Order Regarding Case Consolidation by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Silver, Daniel) |
| Aug 3, 2021 | 25 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME the Deadline for Plaintiffs to file their Answering Brief in Opposition to Defendants Motion to Dismiss Under Fed. R. Civ. P. 12(b)(6) to August 12, 2021 - filed by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Joyce, Alexandra) |
| Jul 23, 2021 | 24 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME (and proposed order) for defendants Actavis Elizabeth LLC, Actavis LLC, and Teva Pharmaceuticals USA, Inc. to answer, move, or otherwise respond to plaintiff's complaint to August 12, 2021 - filed by Actavis Elizabeth LLC, Actavis LLC, Teva Pharmaceuticals USA, Inc.. (Russell, Andrew) |
| Jul 19, 2021 | 23 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME the Deadline for Plaintiffs to file their Answering Brief in Opposition to Defendants Motion to Dismiss Under Fed. R. Civ. P. 12(b)(6) to August 5, 2021 - filed by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Silver, Daniel) |
| Jul 9, 2021 | 22 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Ltd. for Lupin Pharmaceuticals, Inc. filed by Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Haney, Megan) |
| Jul 8, 2021 | 17 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Ltd. for Aurobindo Pharma USA, Inc.; Corporate Parent Aurobindo Pharma USA, Inc. for Aurolife Pharma LLC filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Aurolife Pharma LLC. (Hitch, Cortlan) |
| Jul 8, 2021 | 18 | Main Document (5) Docket Text: MOTION to Dismiss for Failure to State a Claim - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Aurolife Pharma LLC, Cadila Healthcare Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Text of Proposed Order)(Kraman, Pilar) |
| Jul 8, 2021 | 18 | Text of Proposed Order (1) |
| Jul 8, 2021 | 19 | Opening Brief in Support (13) Docket Text: OPENING BRIEF in Support re [18] MOTION to Dismiss for Failure to State a Claim filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Aurolife Pharma LLC, Cadila Healthcare Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc..Answering Brief/Response due date per Local Rules is 7/22/2021. (Kraman, Pilar) |
| Jul 8, 2021 | 20 | Disclosure Statement (4) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Cadila Healthcare Limited for Zydus Pharmaceuticals (USA) Inc. filed by Zydus Pharmaceuticals (USA) Inc.. (Kraman, Pilar) |
| Jul 8, 2021 | 21 | Disclosure Statement (4) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Cadila Healthcare Ltd.. (Kraman, Pilar) |
| Jul 7, 2021 | 16 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for Lupin Pharmaceuticals, Inc. to answer, move or otherwise respond to the Complaint to July 15, 2021 - filed by Lupin Pharmaceuticals, Inc.. (Phillips, John) |
| Jul 2, 2021 | 15 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME move, plead or otherwise respond to the Complaint to July 29, 2021 - filed by Actavis Elizabeth LLC, Actavis LLC, Teva Pharmaceuticals USA, Inc.. (Russell, Andrew) |
| Jun 22, 2021 | 14 | Exhibit A-B (7) |
| Jun 22, 2021 | 14 | Main Document (2) Docket Text: DECLARATION of Service for Defendant Zydus Pharmaceuticals (USA) Inc. made on June 17, 2021 by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Jun 22, 2021 | 13 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Astellas Pharma Global Development, Inc., Astellas Ireland Co., Ltd., Astellas Pharma Inc.. Teva Pharmaceuticals USA, Inc. served on 6/17/2021, answer due 7/8/2021. (Silver, Daniel) |
| Jun 22, 2021 | 12 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Astellas Pharma Global Development, Inc., Astellas Ireland Co., Ltd., Astellas Pharma Inc.. Lupin Pharmaceuticals, Inc. served on 6/17/2021, answer due 7/8/2021. (Silver, Daniel) |
| Jun 22, 2021 | 11 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Astellas Pharma Global Development, Inc., Astellas Ireland Co., Ltd., Astellas Pharma Inc.. Aurolife Pharma LLC served on 6/17/2021, answer due 7/8/2021. (Silver, Daniel) |
| Jun 22, 2021 | 10 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Astellas Pharma Global Development, Inc., Astellas Ireland Co., Ltd., Astellas Pharma Inc.. Aurobindo Pharma USA, Inc. served on 6/17/2021, answer due 7/8/2021. (Silver, Daniel) |
| Jun 22, 2021 | 9 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Astellas Pharma Global Development, Inc., Astellas Ireland Co., Ltd., Astellas Pharma Inc.. Actavis LLC served on 6/17/2021, answer due 7/8/2021. (Silver, Daniel) |
| Jun 22, 2021 | 8 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Astellas Pharma Global Development, Inc., Astellas Ireland Co., Ltd., Astellas Pharma Inc.. Actavis Elizabeth LLC served on 6/17/2021, answer due 7/8/2021. (Silver, Daniel) |
| Apr 2, 2021 | 7 | Certification of J. Leonard (1) |
| Apr 2, 2021 | 7 | Certification of S. Roberts (1) |
| Apr 2, 2021 | 7 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Simon D. Roberts and Jason A. Leonard - filed by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Attachments: # (1) Certification of S. Roberts, # (2) Certification of J. Leonard)(Silver, Daniel) |
| Mar 31, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Joseph F. Bataillon of the U.S. District Court for the District of Nebraska, due to related cases. Please include the initials of the Judge (JFB) after the case number on all documents filed. (rjb) |
| Mar 24, 2021 | 1 | Complaint* (1) |
| Mar 24, 2021 | 6 | Summons Issued - Electronic (2) Docket Text: Summonses Issued (please complete the top portion of the form and print out for use/service). (kmd) |
| Mar 24, 2021 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Astellas B.V. for Astellas Ireland Co., Ltd.; Corporate Parent Astellas US Holding, Inc. for Astellas Pharma Global Development, Inc. - filed by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc. (kmd) |
| Mar 24, 2021 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,842,780. (kmd) |
| Mar 24, 2021 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 3/9/2021, 3/16/2021, 3/3/2021, 2/8/2021. Date of Expiration of Patent: 9/28/2029.Thirty Month Stay Deadline: See Attached. (kmd) |
| Mar 24, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (kmd) |
| Mar 24, 2021 | 1 | Civil Cover Sheet (2) |
| Mar 24, 2021 | 1 | Exhibit A (17) |
| Mar 24, 2021 | 1 | Main Document (20) Docket Text: COMPLAINT for Patent Infringement filed against Actavis Elizabeth LLC, Actavis LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Aurolife Pharma LLC, Cadila Healthcare Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Zydus Pharmaceuticals (USA) Inc. - Magistrate Consent Notice to Pltf. (Filing fee $402, receipt number ADEDC-3578624.) - filed by Astellas Pharma Global Development, Inc., Astellas Ireland Co., Ltd., Astellas Pharma Inc. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(kmd) |
